Fundraising Fox
Accunea
Founded 2017 · 8 employees on LinkedIn · 1 known investors
Find your way into Accunea
Sign up to see every warm intro you have to Accunea
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Accunea team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Accunea develops organ condition monitoring technology that tracks biomarkers of kidney function and metabolism before and after transplantation, providing clinicians with continuous point-of-care data and AI-driven trend analysis. It serves transplant centres and clinicians to assess organ viability and support patient recovery, and integrates with hospital EPR systems.
Founders & leadership
PS
Paul StantonMarket Strategy
Investors · 1
Companies House · registry record
View on Companies House ↗Confirmation statement overdue
- Registered name
- ACCUNEA LTD.
- Company number
- 10661414
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 9 Mar 2017
- Registered office
- 25 Church Street, Kidderminster, DY10 2AW
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Mar 2025 · next due 31 Dec 2026
- Confirmation statement
- last made up to 5 Dec 2024 · next due 19 Dec 2025
Current officers · 5
- Warren Robert Delo — director, appointed 20 Apr 2023
- Dylan Evans — director, appointed 19 May 2023
- Robert Michael Learney — director, appointed 9 Mar 2017
- Amita Nand — director, appointed 15 Oct 2023
- John Leslie Sulley — director, appointed 18 Mar 2024
Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Accunea do?
- Accunea develops organ condition monitoring technology that tracks biomarkers of kidney function and metabolism before and after transplantation, providing clinicians with continuous point-of-care data and AI-driven trend analysis. It serves transplant centres and clinicians to assess organ viability and support patient recovery, and integrates with hospital EPR systems.
- Who are Accunea's investors?
- Accunea's investors include Innvotec Ltd..